ATE502641T1 - Kombination aus azd2171 und pemetrexed - Google Patents

Kombination aus azd2171 und pemetrexed

Info

Publication number: ATE502641T1
Authority: AT; Austria
Prior art keywords: azd2171; pemetrexed; human; combination; antiangiogenic
Prior art date: 2005-12-22

Application number

AT06820574T

Other languages

English (en)

Inventor

Stephen Wedge

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-22

Filing date

2006-12-19

Publication date

2011-04-15

2005-12-22 Priority claimed from GB0526132A external-priority patent/GB0526132D0/en

2006-05-31 Priority claimed from GB0610708A external-priority patent/GB0610708D0/en

2006-12-19 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE502641T1 publication Critical patent/ATE502641T1/de

Links

XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 title abstract 6
229960002412 cediranib Drugs 0.000 title abstract 6
QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 title abstract 6
229960005079 pemetrexed Drugs 0.000 title abstract 6
241001465754 Metazoa Species 0.000 abstract 3
206010028980 Neoplasm Diseases 0.000 abstract 3
238000004519 manufacturing process Methods 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
230000001772 anti-angiogenic effect Effects 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
230000005855 radiation Effects 0.000 abstract 2
230000001603 reducing effect Effects 0.000 abstract 2
230000008728 vascular permeability Effects 0.000 abstract 2
239000013066 combination product Substances 0.000 abstract 1
229940127555 combination product Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Ink Jet (AREA)
Plural Heterocyclic Compounds (AREA)

AT06820574T 2005-12-22 2006-12-19 Kombination aus azd2171 und pemetrexed ATE502641T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0526132A GB0526132D0 (en)	2005-12-22	2005-12-22	Combination Therapy
GB0610708A GB0610708D0 (en)	2006-05-31	2006-05-31	Combination therapy
PCT/GB2006/004768 WO2007071970A2 (en)	2005-12-22	2006-12-19	Combination of azd2171 and pemetrexed

Publications (1)

Publication Number	Publication Date
ATE502641T1 true ATE502641T1 (de)	2011-04-15

Family

ID=37964934

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06820574T ATE502641T1 (de)	2005-12-22	2006-12-19	Kombination aus azd2171 und pemetrexed

Country Status (19)

Country	Link
US (1)	US20080306094A1 (de)
EP (1)	EP1965801B1 (de)
JP (1)	JP2009520787A (de)
KR (1)	KR20080077678A (de)
AT (1)	ATE502641T1 (de)
AU (1)	AU2006328201B2 (de)
BR (1)	BRPI0620118A2 (de)
CA (1)	CA2631676A1 (de)
CY (1)	CY1111482T1 (de)
DE (1)	DE602006020919D1 (de)
DK (1)	DK1965801T3 (de)
HR (1)	HRP20110365T1 (de)
IL (1)	IL191797A0 (de)
NO (1)	NO20082566L (de)
NZ (1)	NZ568812A (de)
PL (1)	PL1965801T3 (de)
PT (1)	PT1965801E (de)
SI (1)	SI1965801T1 (de)
WO (1)	WO2007071970A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
MXPA06010755A (es) *	2004-03-23	2006-12-15	Astrazeneca Ab	Terapia de combinacion.
GB0406446D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
KR20080031029A (ko) *	2005-07-06	2008-04-07	아스트라제네카 아베	Ａｚｄ2171 및 젬시타빈에 의한 암의 병용 요법
PL1971338T3 (pl) *	2005-12-22	2011-07-29	Astrazeneca Ab	Połączenie ZD6474 i premetreksedu
US20090221615A1 (en) *	2008-02-29	2009-09-03	Guru Reddy	Combination anti-cancer agents
JP6182313B2 (ja)	2010-03-08	2017-08-16	スペクトラムファーマシューティカルズインコーポレイテッド	癌治療のためのチオキサントンをベースとしたオートファジー阻害剤療法
EP3328387B1 (de) *	2015-07-30	2020-07-22	Expression Pathology, Inc.	Quantifizieren von fr- und gart-proteinen für eine optimale krebstherapie

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU762615B2 (en) *	1998-06-15	2003-07-03	Arch Development Corporation	Combination of radiotherapy and anti-angiogenic factors
PT1154774E (pt) *	1999-02-10	2005-10-31	Astrazeneca Ab	Derivados de quinazolina como inibidores de angiogenese
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent
GB0316123D0 (en) *	2003-07-10	2003-08-13	Astrazeneca Ab	Combination therapy
GB0316127D0 (en) *	2003-07-10	2003-08-13	Astrazeneca Ab	Combination therapy
GB0330002D0 (en) *	2003-12-24	2004-01-28	Astrazeneca Ab	Quinazoline derivatives
MXPA06010755A (es) *	2004-03-23	2006-12-15	Astrazeneca Ab	Terapia de combinacion.
GB0406446D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
EP1761281A1 (de) *	2004-06-04	2007-03-14	Pfizer Products Incorporated	Verfahren zur behandlung von abnormalem zellwachstum
JP2008514576A (ja) *	2004-09-27	2008-05-08	アストラゼネカアクチボラグ	Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
KR20080031029A (ko) *	2005-07-06	2008-04-07	아스트라제네카 아베	Ａｚｄ2171 및 젬시타빈에 의한 암의 병용 요법
EP1962903B1 (de) *	2005-12-15	2013-03-13	MedImmune Limited	Kombination eines angiopoetin-2-antagonisten und eines vegf-a, kdr- und/oder fltl-antagonisten zur behandlung von krebs
PL1971338T3 (pl) *	2005-12-22	2011-07-29	Astrazeneca Ab	Połączenie ZD6474 i premetreksedu

2006
- 2006-12-19 HR HR20110365T patent/HRP20110365T1/hr unknown
- 2006-12-19 AU AU2006328201A patent/AU2006328201B2/en not_active Ceased
- 2006-12-19 KR KR1020087016943A patent/KR20080077678A/ko not_active Withdrawn
- 2006-12-19 JP JP2008546594A patent/JP2009520787A/ja active Pending
- 2006-12-19 AT AT06820574T patent/ATE502641T1/de active
- 2006-12-19 NZ NZ568812A patent/NZ568812A/en unknown
- 2006-12-19 WO PCT/GB2006/004768 patent/WO2007071970A2/en not_active Ceased
- 2006-12-19 CA CA002631676A patent/CA2631676A1/en not_active Abandoned
- 2006-12-19 DE DE602006020919T patent/DE602006020919D1/de active Active
- 2006-12-19 SI SI200631009T patent/SI1965801T1/sl unknown
- 2006-12-19 DK DK06820574.9T patent/DK1965801T3/da active
- 2006-12-19 PT PT06820574T patent/PT1965801E/pt unknown
- 2006-12-19 EP EP06820574A patent/EP1965801B1/de not_active Not-in-force
- 2006-12-19 BR BRPI0620118-0A patent/BRPI0620118A2/pt not_active Application Discontinuation
- 2006-12-19 US US12/158,266 patent/US20080306094A1/en not_active Abandoned
- 2006-12-19 PL PL06820574T patent/PL1965801T3/pl unknown
2008
- 2008-05-28 IL IL191797A patent/IL191797A0/en unknown
- 2008-06-02 NO NO20082566A patent/NO20082566L/no not_active Application Discontinuation
2011
- 2011-05-20 CY CY20111100490T patent/CY1111482T1/el unknown

Also Published As

Publication number	Publication date
WO2007071970A2 (en)	2007-06-28
HRP20110365T1 (hr)	2011-06-30
SI1965801T1 (sl)	2011-06-30
EP1965801A2 (de)	2008-09-10
BRPI0620118A2 (pt)	2011-11-01
CY1111482T1 (el)	2015-08-05
AU2006328201A1 (en)	2007-06-28
PL1965801T3 (pl)	2011-07-29
JP2009520787A (ja)	2009-05-28
PT1965801E (pt)	2011-05-25
EP1965801B1 (de)	2011-03-23
NZ568812A (en)	2011-09-30
HK1123976A1 (en)	2009-07-03
KR20080077678A (ko)	2008-08-25
IL191797A0 (en)	2008-12-29
DK1965801T3 (da)	2011-06-14
AU2006328201B2 (en)	2010-08-19
US20080306094A1 (en)	2008-12-11
NO20082566L (no)	2008-07-31
DE602006020919D1 (de)	2011-05-05
WO2007071970A3 (en)	2007-08-09
CA2631676A1 (en)	2007-06-28

Legal Events

Date

Code

Title

Description

2011-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1965801

Country of ref document: EP

Publication	Publication Date	Title
CY1111547T1 (el)	2015-08-05	Συνδυασμος zd6474 και πεμετρεξεδης
CY1111482T1 (el)	2015-08-05	Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003505A (es)	2007-05-10	Combinacion que comprende zd6474 e imatinib.
MX2007003506A (es)	2007-05-10	Terapia de combinacion de cancer que comprende azd2171 e imatinib.
PL1653964T3 (pl)	2009-01-30	Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
NO20064755L (no)	2006-10-20	Kombinasjonsterapi
NO20064754L (no)	2006-10-20	Kombinasjonsterapi
NO20056171L (no)	2006-02-07	Kombinasjonsterapi
WO2005092384A3 (en)	2006-11-02	Combination therapy with azd2171 and a platinum anti-tumour agent
WO2007003933A3 (en)	2007-12-27	Combination therapy of cancer with azd2171 and gemcitabine